Sebrinoflast (Compound 5) is a NLRP3 inhibitor with an IC50 ≤1  μM for hNLRP3. Sebrinoflast can be used for inflammatory and cardiovascular diseases including NASH and atherosclerosis and neurological diseases like Alzheimer's disease research.

IIIM-1266 is a NLRP3 inflammasome inhibitor. IIIM-1266 inhibits IL-1β release in mouse macrophages (J774A.1 cells) (IC50 = 2.3 μM) and significantly reduced the protein expression level of mature IL-1β. IIIM-1266 can be used for the study of inflammation.

JNJ-79883960 is a NLRP3 inhibitor. JNJ-79883960 can be used for the study of inflammation.

BAL-1516 is a brain-penetrant and highly selective NLRP3 inhibitor (IC50=14.2 nM). BAL-1516 significantly suppresses IL-1β and IL-18 release in microglial neuroinflammation models (IC50=11-59 nM). BAL-1516 is promising for research of neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) and systemic inflammatory disorders.

NP3-742 is an orally active NLRP3 inhibitor that binds to the NLRP3 NACHT domain. NP3-742 inhibits IL-1β release with IC50s of 6 nM and 47 nM in both the cellular and whole blood assays, respectively. NP3-742 is highly selective against a panel of more than 50 enzymes, receptors and sodium and calcium channels. NP3-742 can be used for the study of gout, cardiovascular disease or osteoarthritis.

GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells.

VEN-02XX is an orally active and brain-permeable NLRP3 inhibitor. VEN-02XX inhibits the release of IL-1β and IL-18 (IC50 0.3 and 0.28 μM, respectively). VEN-02XX restores memory and cognition, inhibits microgliosis, and reduces neuroinflammation and tau pathology in the 5XFAD/Rubicon KO mouse model. VEN-02XX may be used in the study of Alzheimer's disease (AD).

NP3-253 is an NLRP3 inhibitor with oral activity and blood-brain barrier permeability, and NP3-253 can serve as a tool to further investigate the biological characteristics of NLRP3 in peripheral and neuroinflammatory model.

HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a KD value of 204.6 nM and an IC50 of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC50 of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis.

JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects.

DFV890 (IFM-2427) is apotent, selective and orally active inhibitor of NLRP3 inflammasome, directly binds to NLRP3 and locks the protein in an inactive conformation,prevents NLRP3 inflammasome assembly in response to sterile danger signals.

MCC7840 sodium, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. MCC7840 sodium can be used for the research of inflammatory diseases.

Selnoflast (example 6) is a NLRP3 inhibitor (extracted from patent WO2019008025).

ZYIL1 is an oral small molecule NLRP3 inflammasome inhibitor, exhibits potent (IC50 in nanomolar range) in human whole blood and supresses inflammation caused by the NLRP3 inflammasome.

NP3-146 is a small molecule NLRP3 inflammasome inhibitor and an analog of MCC950.

NLRP3-inhibitory compound 7 (NIC7) is a small-molecule inhibitor of Nod-like receptor family pyrin domain-containing 3 (NLRP3), inhibits NLRP3-mediated activation of caspase 1 along with the secretion of IL-1β, IL-18, and lactate dehydrogenase.

NDT-19795 is the carboxylic acid metabolite of selective NLRP3 inhibitor NT-0796, suppresses release of IL-1β in LPS-activated human PBMCs with IC50 of 47 nM.

ML146 (ML-146, Pubmed CID-1088438) is a selective small molecule NOD1 inhibitor with IC50 of 1.5 uM in NOD1 agonist-stimulated NF-κB reporter assay in HEK293T cells.

JT002 is a potent and selective inhibitor of NLRP3 inflammasome with IC50 of 6 nM (IL-1β production from hPBMCs), inhibits NLRP3 mediated cytokine production and pyroptosis.

JT001 (JT-001) is a potent, highly specific NLRP3 inhibitor, inhibits NLRP3 inflammasome assembly.

JC2-11 is an anti-inflammasome compound and a pan-inhibitor of the NLRP3, NLRC4, and AIM2 inflammasomes.

FK565 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist.

FK156 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist.

ADS032 (ADS-032) is the first, reversible and stable dual NLRP1 and NLRP3 inflammasome inhibitor, inhibits nigericin-induced NLRP3-induced IL-1β secretion from LPS-primed iBMDMs with IC50 of 30 uM.

NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.

MCC950 (CP-456773) sodium is a potent, selective, small-molecule inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs.

INF39 is an irreversible and noncytotoxic NLRP3 inhibitor.

CY-09 is an NLRP3 inhibitor.

NDT-30805 is a selective NLRP3 inflammasome inhibitor. NDT-30805 is a triazolopyrimidinone derivative and inhibits IL-1β release in PBMCs with an IC50 of 0.013 μM. NDT-30805 can be used for the research of inflammation and innate immunity.

AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders.